Patents Assigned to Bioscience, Inc.
  • Cell maintainer for autologous cell therapy production
    Patent number: 11879120
    Abstract: In some aspects, the invention relates to automated cell culture incubators and their methods of use. In one aspect, the disclosure provides cell culture incubators having an airlock chamber, a storage chamber and/or an internal chamber. In some aspects, the disclosure provides methods for producing autologous mammalian cell cultures.
    Type: Grant
    Filed: September 30, 2021
    Date of Patent: January 23, 2024
    Assignee: Thrive Bioscience, Inc.
    Inventor: Alan Blanchard
  • POLYNUCLEOTIDES ENCODING ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR RECOGNITION SEQUENCES IN THE DYSTROPHIN GENE
    Publication number: 20240018495
    Abstract: The present disclosure encompasses engineered meganucleases that bind and cleave recognition sequences within a dystrophin gene. The present disclosure also encompasses methods of using such engineered meganucleases to make genetically modified cells. Further, the disclosure encompasses pharmaceutical compositions comprising engineered meganuclease proteins, or polynucleotides encoding engineered meganucleases of the disclosure, and the use of such compositions for the modification of a dystrophin gene in a subject, or for treatment of Duchenne Muscular Dystrophy.
    Type: Application
    Filed: July 27, 2023
    Publication date: January 18, 2024
    Applicant: Precision BioSciences, Inc.
    Inventors: Gary Owens, Janel Lape, James Jefferson Smith, John Morris, Caitlin Turner, Whitney Lewis, Derek Jantz
  • Compositions and methods for expression of IL-12 and IL-1RA
    Patent number: 11873507
    Abstract: The present disclosure relates to the field of molecular virology, and particularly relates to nucleic acid molecules encoding a modified alphavirus virus viral genome or self-replicating RNA (srRNA) construct, pharmaceutical compositions containing the same, and the use of such nucleic acid molecules and compositions for production of desired products in cell cultures or in a living body. Also provided are methods for eliciting a pharmacodynamics effect in a subject.
    Type: Grant
    Filed: November 29, 2021
    Date of Patent: January 16, 2024
    Assignee: Replicate Bioscience, Inc.
    Inventors: Nathaniel Stephen Wang, Shigeki Joseph Miyake-Stoner, Parinaz Aliahmad
  • Subtyping prostate cancer to predict response to hormone therapy
    Patent number: 11873532
    Abstract: The present invention relates to methods, systems and kits for the diagnosis, prognosis and the determination of progression of cancer in a subject. The invention also provides biomarkers that define subgroups of prostate cancer, clinically useful classifiers for distinguishing prostate cancer subtypes, bioinformatic methods for determining clinically useful classifiers, and methods of use of each of the foregoing. The methods, systems and kits can provide expression-based analysis of biomarkers for purposes of subtyping prostate cancer in a subject. Further disclosed herein, in certain instances, are probe sets for use in subtyping prostate cancer in a subject. Classifiers for subtyping a prostate cancer are provided. Methods of treating cancer based on molecular subtyping are also provided.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: January 16, 2024
    Assignees: Decipher Biosciences, Inc., 2. The Regents of the University of Michigan
    Inventors: Elai Davicioni, Nicholas Erho, Shuang G. Zhao, S. Laura Chang, Felix Y. Feng
  • ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE TRANSTHYRETIN GENE
    Publication number: 20240011003
    Abstract: The present invention encompasses engineered meganucleases that bind and cleave a recognition sequence within a TTR gene. The present invention also encompasses methods of using such engineered meganucleases to make genetically-modified cells. Further, the invention encompasses pharmaceutical compositions comprising engineered meganuclease proteins, or nucleic acids encoding engineered meganucleases of the invention, and the use of such compositions for treatment of TTR-associated diseases, such as transthyretin amyloidosis.
    Type: Application
    Filed: August 20, 2021
    Publication date: January 11, 2024
    Applicant: Precision Biosciences, Inc.
    Inventors: Cassandra Gorsuch, Jochen Genschel, Janel Lape, Derek Jantz, James Jefferson Smith
  • Pyrimidine and pyridine amine compounds and usage thereof in disease treatment
    Patent number: 11866421
    Abstract: Pyrimidine and Pyridine containing compounds are described herein that are enzyme p70S6K inhibitors useful in the treatment of S6K-dependent or S6K-mediated diseases and conditions, including but not limited to cancer, fibrotic metabolic and certain neurological disorders.
    Type: Grant
    Filed: May 31, 2021
    Date of Patent: January 9, 2024
    Assignee: Epigen Biosciences, INC.
    Inventors: Graham Beaton, Fabio Tucci, Satheesh Ravula, Suk Joong Lee, Chandravadan Shah
  • Multi-omic analysis in monodisperse droplets
    Patent number: 11866782
    Abstract: This disclosure provides methods and systems for single-cell, multi-omic analysis of target cells without microfluidic devices. The disclosed methods involve the use of template particles to template the formation of monodisperse droplets to generally capture a single target cell from a population of cells in an encapsulation, derive a plurality of distinct mRNA molecules from the single target cell, and quantify the distinct mRNA molecules to generate an expression profile. Nucleic-acid-tagged antibody conjugates are used for simultaneous proteomic analysis along with the gene expression profiling.
    Type: Grant
    Filed: March 16, 2021
    Date of Patent: January 9, 2024
    Assignee: Fluent Biosciences Inc.
    Inventor: Sepehr Kiani
  • Engineered meganucleases that target human mitochondrial genomes
    Patent number: 11866747
    Abstract: Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human mitochondrial DNA (mtDNA). The disclosure further relates to the use of such recombinant meganucleases in methods for producing genetically-modified eukaryotic cells, and to a population of genetically-modified eukaryotic cells wherein the mtDNA has been having modified or edited.
    Type: Grant
    Filed: January 30, 2023
    Date of Patent: January 9, 2024
    Assignees: University of Miami, Precision BioSciences, Inc.
    Inventors: James Jefferson Smith, Ginger Tomberlin, John Morris, Wendy Shoop, Carlos T. Moraes
  • Spatially encoded biological assays
    Patent number: 11866770
    Abstract: The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.
    Type: Grant
    Filed: May 26, 2023
    Date of Patent: January 9, 2024
    Assignee: Prognosys Biosciences, Inc.
    Inventor: Mark S. Chee
  • POLYNUCLEOTIDES ENCODING ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR RECOGNITION SEQUENCES IN THE DYSTROPHIN GENE
    Publication number: 20240002823
    Abstract: The present disclosure encompasses engineered meganucleases that bind and cleave recognition sequences within a dystrophin gene. The present disclosure also encompasses methods of using such engineered meganucleases to make genetically modified cells. Further, the disclosure encompasses pharmaceutical compositions comprising engineered meganuclease proteins, or polynucleotides encoding engineered meganucleases of the disclosure, and the use of such compositions for the modification of a dystrophin gene in a subject, or for treatment of Duchenne Muscular Dystrophy.
    Type: Application
    Filed: July 27, 2023
    Publication date: January 4, 2024
    Applicant: Precision BioSciences, Inc.
    Inventors: Gary Owens, Janel Lape, James Jefferson Smith, John Morris, Caitlin Turner, Whitney Lewis, Derek Jantz
  • GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
    Publication number: 20240002796
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Application
    Filed: January 17, 2023
    Publication date: January 4, 2024
    Applicant: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • OPTIMIZED ENGINEERED NUCLEASES HAVING SPECIFICITY FOR THE HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
    Publication number: 20240000845
    Abstract: The present invention encompasses engineered nucleases which recognize and cleave a recognition sequence within the first exon of the human T cell receptor (TCR) alpha constant region gene. The engineered meganucleases can exhibit at least one optimized characteristic, such as enhanced (i.e., increased) specificity or efficiency of cleavage, when compared to the first-generation meganuclease TRC 1-2x.87EE. The present invention also encompasses methods of using such engineered nucleases to make genetically-modified cells, and the use of such cells in a pharmaceutical composition and in methods for treating diseases, such as cancer.
    Type: Application
    Filed: September 5, 2023
    Publication date: January 4, 2024
    Applicant: Precision BioSciences, Inc.
    Inventors: James Jefferson Smith, Janel Lape, Hui Li, Jochen Genschel
  • Compositions and methods for pairwise sequencing
    Patent number: 11859241
    Abstract: The present disclosure provides compositions and methods that employ the compositions for conducting pairwise sequencing and for generating concatemer template molecules for pairwise sequencing. The concatemers can be generated using a rolling circle amplification reaction which is conducted either on-support, or conducted in-solution and then distributed onto a support. The rolling circle amplification reaction generates concatemers containing tandem copies of a sequence of interest and at least one universal adaptor sequence. An increase in the number of tandem copies in a given concatemer increases the number of sites along the concatemer for hybridizing to multiple sequencing primers which serve as multiple initiation sites for polymerase-catalyzed sequencing reactions. When the sequencing reaction employs detectably labeled nucleotides and/or detectably labeled multivalent molecules (e.g.
    Type: Grant
    Filed: February 8, 2023
    Date of Patent: January 2, 2024
    Assignee: Element Biosciences, Inc.
    Inventors: Sinan Arslan, Junhua Zhao, Molly He, Samantha Snow, William Light, Matthew Kellinger, Michael Previte, Michael Kim, Hua Yu, Yu-Hsien Hwang-Fu, Marco Tjioe, Andrew Boddicker, Mark Ambroso, Tyler Lopez, Michael Klein, Virginia Saade
  • Methods and compositions for treating polycystic ovary syndrome
    Patent number: 11858932
    Abstract: Polycystic ovary syndrome (PCOS) is characterized by elevated levels of androgens, cysts in the ovaries, and irregular periods. Women with PCOS present with additional symptoms, including hirsutism, alopecia, acne, infertility, weight gain, fatigue, depression and mood changes. The present disclosure provides new compounds, salts, compositions and uses thereof in the treatment of PCOS due to elevated adrenal androgens. Further, the present disclosure provides methods for treating PCOS due to elevated adrenal androgens.
    Type: Grant
    Filed: June 13, 2023
    Date of Patent: January 2, 2024
    Assignee: Spruce Biosciences, Inc.
    Inventors: Christopher Barnes, David Karpf, Mustafa Noor
  • RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
    Publication number: 20230416711
    Abstract: Disclosed are rationally-designed, non-naturally-occurring meganucleases in which a pair of enzyme subunits having specificity for different recognition sequence half-sites are joined into a single polypeptide to form a functional heterodimer with a non-palindromic recognition sequence. The invention also relates to methods of producing such meganucleases, and methods of producing recombinant nucleic acids and organisms using such meganucleases.
    Type: Application
    Filed: March 17, 2023
    Publication date: December 28, 2023
    Applicant: Precision Biosciences, Inc.
    Inventors: James Jefferson Smith, Derek Jantz
  • SYSTEMS AND METHODS FOR PRODUCING STERILE INJECTION DEVICES
    Publication number: 20230414800
    Abstract: The present disclosure provides novel processes for providing sterile, pre-filled syringes or injection devices for pharmaceutical compositions, including protein and biopharmaceutical formulations. In some examples, secondary packaging is performed in an aseptic environment, which removes the need for any terminal sterilization method. In some examples, the aseptic packaging method results in a sterile injection device suitable for use in ophthalmic injections.
    Type: Application
    Filed: September 11, 2023
    Publication date: December 28, 2023
    Applicant: Coherus Biosciences, Inc.
    Inventors: Wendy SHIEU, Gerald LLORACH
  • POTENT AND SELECTIVE INHIBITORS OF THE CALCIUM-ACTIVATED POTASSIUM CHANNEL, KCA3.1, FOR USE AS PLATFORM THERAPEUTICS
    Publication number: 20230416203
    Abstract: Provided is the use of compounds of Formula I, as well as certain specific compounds, or a pharmaceutically acceptable salt, solvate or derivative thereof, in the preparation of a medicament to treat or prevent a disease condition that is associated with increased KCa3.1 or altered activity, such as stroke.
    Type: Application
    Filed: November 30, 2021
    Publication date: December 28, 2023
    Applicants: Nanyang Technological University, Ice Bioscience Inc.
    Inventors: George Kanianthara CHANDY, Seow Theng ONG, Yingji LI
  • Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)
    Patent number: 11851680
    Abstract: The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein. Methods for reducing the expression of an endogenous protein in an immune cell are also provided wherein the method comprises introducing a shRNAmiR that targets the endogenous protein. Using shRNAmiRs for knocking down the expression of a target protein allows for stable knockdown of expression of endogenous proteins in immune cells.
    Type: Grant
    Filed: August 17, 2022
    Date of Patent: December 26, 2023
    Assignee: Precision Biosciences, Inc.
    Inventors: Aaron Martin, Jon E. Chatterton, Michelle Brenda Pires
  • METHODS AND APPARATUS FOR REMOVABLE NOZZLE WITH CAM LATCH ENGAGEMENT IN FLOW CYTOMETERS
    Publication number: 20230405592
    Abstract: A flow cell subassembly includes a carriage assembly coupled to a flow cell body to selectively engage a nozzle with a base of a cuvette. The carriage assembly includes a linear bearing slidingly engaged with the flow cell body, a tiltable carriage plate coupled to the linear bearing, and a nozzle mount coupled to the tiltable carriage plate. The nozzle mount receives a nozzle assembly with the nozzle. Set screws can adjust pitch angle of the tiltable carriage plate with the linear bearing to adjust engagement between the nozzle and cuvette in a first dimension. To adjust engagement between the nozzle and cuvette in a second dimension, axial play in bolts/screws through the tiltable carriage plate into threaded holes of the linear bearing allow for yaw angle adjustments.
    Type: Application
    Filed: April 8, 2023
    Publication date: December 21, 2023
    Applicant: Cytek Biosciences, Inc.
    Inventors: Kuncheng Wang, Huimin Gu, Andrew Klyce-Mariscal, Wing Lee, Ming Yan, Glen Krueger, David Vrane
  • SOLID FORMS OF CANNABIDIOL AND USES THEREOF
    Publication number: 20230404939
    Abstract: Disclosed herein are cocrystals of cannabidiol and a coformer containing 5-6 membered rings comprised of carbon and nitrogen atoms, wherein the 5-6 membered rings can be unsaturated or saturated and the rings contain 1 to 2 nitrogen atoms.
    Type: Application
    Filed: June 20, 2022
    Publication date: December 21, 2023
    Applicant: Artelo Biosciences, Inc.
    Inventors: R. Martin Emanuele, Tanise Shattock-Gordon, Tabitha Williford, Mark Andres, Patricia Andres